Despite these developments, NSCLC patients’ platinum-refractory with non-KRAS G12C mutation is still a therapeutic challenge, and the high cost of these anti-KRAS inhibitors constitutes an important barrier in low and middle-income countries. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.